PP147-CYP2D6 GeNeTiC PolYmorPhiSmS AmoNG Three CoSTA riCAN PoPulATioNS
C. Céspedes Garro 1,2* ; G. Jiménez-Arce 1 ; M.E.G. Naranjo 2 ; R. Barrantes 1 ; A.L Lerena 2 ; and CEIBA Consortium 1 School of Biology, University of Costa Rica, San José, Costa Rica; and 2 CICAB, Clinical Research Centre, Extremadura University Hospital and Medical School, Badajoz, Spain Introduction: CYP2D6 differences have already been demonstrated within Latin-American populations by the Iberoamerican Network of Pharmacogenetic CEIBA Consortium. However, until now, no other investigations have been developed within Costa Rica's population, which is of interest becuase this population has a trihybrid component ancestry. The present study was aimed to determine the frequency of CYP2D6 predicted phenotype within 3 Costa Rican groups with different ethnic backgrounds and to describe CYP2D6 genotypes and allele frequencies compared with other Latin-American populations. Patients (or Materials) and Methods: Three hundred eighty-five individuals were included in the study (139 Mestizo/CRM, 197 Amerindians/AM, and 49 Afro-Caribbeans/AC). XL-PCR and realtime PCR were performed to determine CYP2D6 genotypes. The CYP2D6 variant alleles *2, *3, *4, *5, *6, *10, *17, *29, *35 and *41 were determined.
Results:
The highest frequencies of UMs (10.1%) and PMs (10.2%) were found in the CRM and AM population, respectively. Multiplication of active genes (5.4%) were responsible for the high frequency of UMs in CRM population, and the presence of CYP2D6*4 (22.6%) for PMs in AM group. As expected, CYP2D6*17 and *29 were higher in AC group, 18.4 and 11.2% respectively. However, *10 was lower in the AM population (0.3%). Conclusion: CYP2D6 predicted phenotypes vary for UMs from 10.1 to 3.6% and PMs from 10.2 to 1.4%, among 3 Costa Rican groups with different ethnic background. In addition, CYP2D6 genotype and allele frequencies of the Costa Rican population studied differ in comparison to other Latin-American populations. Funding Sources: This study was supported by the University of Costa Rica (CCG, GJ, RB), Plan Nacional de Investigación Científica, Desarrollo e Innovación Tecnológica (I+D+I) and Fondo Social Europeo of the European Union (FEDER) PI10/02758, Gobierno de Extremadura, Consejería de Empleo, Empresa e Innovación and Fondo Social Europeo (FSE) Grant PD10199 (MEGN) and AEXCID 11IA002, and coordinated in the network Red Iberoamericana de Farmacogenética y Farmacogenómica CEIBA F.P. Consortium. Disclosure of Interest: None declared. Recently, a single nucleotide polymorphism (SNP) IVS8-109A> T linked to SNPs in the 5'-UTR, exon 1 and intron 1 of the CYP2C9 gene 1 has been described in association with a higher CYP2C9 losartan metabolic ratio (MR) in healthy Swedes. 2 The aim of this study was to examine whether there is a relationship between the CYP2C9 polymorphism IVS8-109A> T and the losartan/E3174 MR, in a previously studied healthy population of Ecuadorians. 3 Patients (or Materials) and Methods: The CYP2C9 IVS8-109A> T polymorphism was analyzed in 161 unrelated Ecuadorian subjects using a specific PCR-RFLP method. 2 These participants had been previously genotyped for CYP2C9 alleles *2, *3, *4, *5 and *6 and phenotyped with a single oral dose of 25 mg losartan, 3 and all of them were CYP2C9*1/*1. Results: The frequency of the allelic IVS8-109A> T polymorphism in this study was 0.23. The urinary losartan/E3174 ratio was significantly higher (p = 0.024; Student t test) in subjects with the A/A (IVS8-109) genotype (mean [SD], 5.1 [6.6]; n = 95) than in subjects with T/T (2.3 [3.7]; n = 8). Present results show that the IVS8-109T allele is associated with a lower CYP2C9 MR in this healthy population of Ecuadorian subjects, which is in disagreement with previous findings in healthy Swedes that reported the IVS8-109T allele in association with a higher CYP2C9 MR. 2 Conclusion: This study shows that the SNP IVS8-109T allele is associated with a lower CYP2C9 MR, but further investigations need to be carried out to establish a molecular explanation for ultra-rapid CYP2C9-catalyzed metabolism. Funding Sources: The study has been partly supported by the Institute of Health Carlos III-FIS and the European Union (FEDER) Grants PI10/02010 and PI10/02758; Gobierno de Extremadura and e65 AEXCID Cooperación Extremeña (11IA002) , and coordinated in the Iberoamerican Network of Pharmacogenetics (SIFF). Disclosure of Interest: None declared. references 1. Maekawa, et al. Pharmacogenet Genomics. 2006; 16:497-514. 2. Hatta, et al. Eur J Clin Pharmacol. 2012; 68:1033 -1042 . 3. Dorado, et al. Pharmacogenomics. 2012 13:1711 -1717 (EMA, 2013) . Therefore, a novel cocktail approach to measure metabolic activity (metabolic ratios) of the main CYP enzymes in just one experiment is developed and validated to be used in the study of Latin-American populations. Patients (or Materials) and Methods: Subjects were given low oral doses of 100-mg caffeine, 25-mg losartan, 20-mg omeprazole, and 30-mg dextromethorphan. Blood samples were taken 4 hours after administering the drugs to assay the following metabolic ratios in plasma: CYP1A2 (caffeine/paraxanthine), CYP2C9 (losartan /E-3174), CYP2C19 (omeprazole/5-hydroxyomeprazole), CYP2D6 (dextromethorphan/ dextrorphan), and CYP3A4 (dextromethorphan/3-methoxymorphinan). Solid phase extraction was utilized for analyte extraction and LC-MS/MS to quantify the probe drugs and metabolites. Results: Recovery values > 80% were obtained for all analytes, and no carryover or relative matrix effects were observed. The analytes were separated and detected in 9 minutes and the method was fully validated, with lower limits of quantification ranging from 0.3 ng mL-1 for 5-hydroxyomeprazole to 3.2 ng mL-1 for paraxanthine. The correlation coefficient (r2) values obtained were over 0.995 for all analytes. According to the EMA guideline on bioanalytical method validation, precision and accuracy values below 15% were achieved. Conclusion: The method was proven to be useful to measure targeted analytes for the evaluation of CYPs hydroxylation capacity in just a single experiment. 
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